Homeopathy may not work but placebo does

On February 22nd the UK government Science and Technology Committee published Evidence Check 2: Homeopathy and concluded that “the NHS should cease funding homeopathy”. Hurrah! 

It also noted that ”the Medicines and Healthcare products Regulatory Agency (MHRA) should not allow homeopathic product labels to make medical claims without evidence of efficacy. As they are not medicines, homeopathic products should no longer be licensed by the MHRA.” Hurrah again. 

But this is the really really interesting bit. “In the Committee’s view,
homeopathy is a placebo treatment and the government  should have a policy on prescribing placebos.”. They go on to say that placebos involve deception, and are not consistent with informed consent.

To which I say: no, no, you miss the point.

Placebos can be deceptive – but the placebo effect needs not be. We
know that longer consultations, continuity of care, and feeling cared for make people get better faster.

So why don’t we start paying more attention to these kinds of things in the NHS?

And what about simple things. We know that flashily branded medicines have a placebo effect beyond that of plain ones. An NHS generics plant which packages with (cost effective) colour and panache may pay
for itself quite easily.

The placebo effect is not a nuisance. It is our best friend, and it needn’t be deceptive

Health and science blog




This blog, part of the FT's health series, is a forum for readers interested in the science, policy, management, technology, business and delivery of healthcare.

This blog is no longer active but it remains open as an archive.
Follow on twitter

About our regular bloggers

Margaret McCartney is a Glasgow-based GP and FT Weekend columnist. She started writing for the Life and Arts section in 2005 and moved to the magazine in 2008. She also has her own blog: www.margaretmccartney.com/blog

Clive Cookson has been a science journalist for the whole of his working life. He joined the FT in 1987. Clive, the FT's science editor, picks out the research that everyone should know about. He also discusses key policy issues, from R&D funding to science education.

Andrew Jack is pharmaceuticals correspondent, covering the industry and public health issues. He has been a journalist with the FT for 19 years, based in London, Paris and Moscow

The Health blog: a guide

Comment: To comment, please register with FT.com, which you can do for free here. Please also read our comments policy here.
Contact: You can write to Ursula Milton, the blog's editor, using this email format: firstname.surname@ft.com
Time: UK time is shown on posts.
Follow: Links to the blog's Twitter and RSS feeds are at the top of the page. You can also read the Health blog on your mobile device, by going to www.ft.com/healthblog
FT blogs: See the full range of the FT's blogs here.